| Literature DB >> 22877636 |
Joerg Bussenius1, Charles M Blazey, Naing Aay, Neel K Anand, Arlyn Arcalas, TaeGon Baik, Owen J Bowles, Chris A Buhr, Simona Costanzo, Jeffrey K Curtis, Steven C DeFina, Larisa Dubenko, Timothy S Heuer, Ping Huang, Christopher Jaeger, Anagha Joshi, Abigail R Kennedy, Angie I Kim, Katherine Lara, Jae Lee, Jonathan Li, Julie C Lougheed, Sunghoon Ma, Shiva Malek, Jean-Claire L Manalo, Jean-Francois Martini, Garth McGrath, Monique Nicoll, John M Nuss, Michael Pack, Csaba J Peto, Tsze H Tsang, Longcheng Wang, Scott W Womble, Michael Yakes, Wentao Zhang, Kenneth D Rice.
Abstract
With structural guidance, tropane-derived HTS hits were modified to optimize for HSP90 inhibition and a desirable in vivo profile. Through an iterative SAR development process 12i (XL888) was discovered and shown to reduce HSP90 client protein content in PD studies. Furthermore, efficacy experiments performed in a NCI-N87 mouse xenograft model demonstrated tumor regression in some dosing regimens.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22877636 DOI： 10.1016/j.bmcl.2012.07.052
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823